Abstract：Objective: To explore the clinical efficacy and safety of levosimendan on patients with acute decompensated heart failure. Methods： One hundred patients met the inclusion criteria were randomly divided into one group with levosimendan andthe other group with milrinone. Clinical efficacy, heart function, BNP and the 24 hourly urine volume, systolic pressure, LVEF, LVEDD and adverse reaction were detected before and after treatment. Results： Both efficiency and total effective rate after treatment in levosimendan group were higher than those in milrinone group (χ2=4.006 and 8.274，P<0.05). Statistical significance of BNP, the 24 hourly urine volume and LVEF was noted in two groups after treatment(P＜0.01).Serum BNP levels decreased, the total 24 hourly urine volume increased and LVEF improved in levosimendan group compared with milrinone group(P<0.01).During the treatment period, occurrences of adverse events in levosimendan group were lower than those in control group (χ2=1.301，P<0.05). Conclusion： Levosimendan was well tolerated and superior to milrinone for patients with decompensated heart failure refractory to conventional medications, because it was able to improve heart function and the symptoms of heart failure by alterring haemodynamic variables.
2012, Vol. 22 
